Postoperative complications in patients with rheumatoid arthritis using a biological agent - A systematic review and meta-analysis

Modern Rheumatology

Volumn 25, Issue 5, 2015, Pages 672-678

  Ito, Hiromu ^a   Kojima, Masayo ^b   Nishida, Keiichiro ^c   Matsushita, Isao ^d   Kojima, Toshihisa ^e   Nakayama, Takeo ^a   Endo, Hirahito ^f   Hirata, Shintaro ^g   Kaneko, Yuko ^h   Kawahito, Yutaka ⁱ   Kishimoto, Mitsumasa ^j   Seto, Yohei ^k   Kamatani, Naoyuki ^k   Tsutani, Kiichiro ^l   Igarashi, Ataru ^l   Hasegawa, Mieko ^m   Miyasaka, Nobuyuki ⁿ   Yamanaka, Hisashi ^k  

^a KYOTO UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c OKAYAMA UNIVERSITY   (Japan)

^d UNIVERSITY OF TOYAMA   (Japan)

^e NAGOYA UNIVERSITY HOSPITAL   (Japan)

^f TOHO UNIVERSITY   (Japan)

^g UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^j ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^k TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^l UNIVERSITY OF TOKYO   (Japan)

^m Japan Rheumatism Friendship Assoc   (Japan)

ⁿ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

more..

Author keywords

Biological agent; Delayed wound healing; Perioperative complication; Rheumatoid arthritis; Surgical site infection; Systematic review

Indexed keywords

BIOLOGICAL DISEASE MODIFYING ANTIRHEUMATIC DRUG; DISEASE MODIFYING ANTIRHEUMATIC DRUG; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT;

ARTICLE; DATA PROCESSING; HUMAN; JOINT PROSTHESIS; META ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK FACTOR; SURGICAL INFECTION; SYSTEMATIC REVIEW; WOUND HEALING IMPAIRMENT; ADVERSE EFFECTS; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; ORTHOPEDIC SURGERY; SURGICAL WOUND INFECTION; WOUND HEALING;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; ORTHOPEDIC PROCEDURES; SURGICAL WOUND INFECTION; WOUND HEALING;

EID: 84940551181     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1014302     Document Type: Article

References (36)

1. Momohara S, Inoue E, Ikari K, Ochi K, Ishida O, Yano K, et al. Recent trends in orthopedic surgery aiming to improve quality of life for those with rheumatoid arthritis: data from a large observational cohort. J Rheumatol. 2014; 41(5): 862-6.
2. Guyatt G, Oxman AD, Akl E, Kunz R, Vist G, Brozek J, et al. GRADE guidelines 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011; 64(4): 383-94.
3. GRADE Working group. Available at: http://www.gradeworkinggroup.org/index.htm. Accessed 20th February, 2015.
4. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in metaanalyses. Ottawa (ON): Ottawa Health Research Institute. Available at: www.ohri.ca/programs/clinical-epidemiology/oxford.asp (accessed on 6 December 2014).
5. Simunovic N, Devereaux P J, Sprague S, Guyatt G H, Schemitsch E, Debeer J, Bhandari M. Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ. 2010; 182(15): 1609-16.
6. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011; 70(10): 1810-4.
7. Suzuki M, Nishida K, Soen S, Oda H, Inoue H, Kaneko A, et al. Risk of postoperative complications in rheumatoid arthritis relevant to treatment with biologic agents: a report from the Committee on Arthritis of the Japanese Orthopaedic Association. J Orthop Sci. 2011; 16(6): 778-84.
8. Hirao M, Hashimoto J, Tsuboi H, Nampei A, Nakahara H, Yoshio N, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2009; 68(5): 654-7.
9. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Iwamoto T, Yano K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? Rheumatology (Oxford). 2010; 49(2): 341-7.
10. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol. 2010; 29(5): 495-500.
11. Momohara S, Kawakami K, Iwamoto T, Yano K, Sakuma Y, Hiroshima R, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with nonbiologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2011; 21(5): 469-75.
12. Kubota A, Nakamura T, Miyazaki Y, Sekiguchi M, Suguro T. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol. 2012; 22(6): 844-8.
13. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int. 2004; 25(5): 331-5.
14. Giles J T, Bartlett S J, Gelber A C, Nanda S, Fontaine K, Ruffing V, Bathon JM. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Rheum. 2006; 55(2): 333-7.
15. den Broeder A A, Creemers M C, Fransen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol. 2007; 34(4): 689-95.
16. Momohara S, Hashimoto J, Tsuboi H, Miyahara H, Nakagawa N, Kaneko A, et al. Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study. Mod Rheumatol. 2013; 23(3): 440-9.
17. Wendling D. Surgery in rheumatoid arthritis patients under anti-TNF-alpha therapy: what is the risk? Clin Rheumatol. 2007; 26(8): 1396-7.
18. Pappas D A, Giles J T. Do antitumor necrosis factor agents increase the risk of postoperative orthopedic infections? Curr Opin Rheumatol. 2008; 20(4): 450-6.
19. Pham T, Bachelez H, Berthelot JM, Blacher J, Bouhnik Y, Claudepierre P, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine. 2011; 78(Suppl 1): 15-185.
20. Goh L, Jewell T, Laversuch C, Samanta A. Should anti-TNF therapy be discontinued in rheumatoid arthritis patients undergoing elective orthopaedic surgery? A systematic review of the evidence. Rheumatol Int. 2012; 32(1): 5-13.
21. Krause M L, Matteson E L. Perioperative management of the patient with rheumatoid arthritis. World J Orthop. 2014; 5(3): 283-91.
22. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011; 50(1): 124-31.
23. Talwalkar S C, Grennan D M, Gray J, Johnson P, Hayton M J. Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis. 2005; 64(4): 650-1.
24. Wendling D, Balblanc J C, Brousse A, Lohse A, Lehuede G, Garbuio P, et al. Surgery in patients receiving anti-tumour necrosis factor alpha treatment in rheumatoid arthritis: an observational study on 50 surgical procedures. Ann Rheum Dis. 2005; 64(9): 1378-9.
25. Ruyssen-Witrand A, Gossec L, Salliot C, Luc M, Duclos M, Guignard S, Dougados M. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol. 2007; 25(3): 430-6.
26. Corrao S, Pistone G, Arnone S, Calvo L, Scaglione R, Licata G. Surgery during etanercept therapy in patients with rheumatoid arthritis: is it time to follow patient preferences? Intern Emerg Med. 2008; 3(1): 73-5.
27. Hayata K, Kanbe K, Chiba J, Nakamura A, Inoue Y, Hobo K. Clinical factors related to the efficacy and complications of orthopedic surgery for rheumatoid arthritis with infliximab. Int J Rheum Dis. 2011; 14(1): 31-6.
28. Gilson M, Gossec L, Mariette X, Gherissi D, Guyot M H, Berthelot J M, et al. Risk factors for total joint arthroplasty infection in patients receiving tumor necrosis factor-blockers: a case-control study. Arthritis Res Ther. 2010; 12(4): R145. doi:10.1186/ar3087. Epub 2010 Jul 16.
29. Berthold E, Geborek P, Gülfe A. Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1, 596 elective orthopedic and hand surgery procedures. Acta Orthop. 2013; 84(5): 495-501.
30. Johnson B K, Goodman S M, Alexiades M M, Figgie M P, Demmer R T, Mandl LA. Patterns and associated risk of perioperative use of antitumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013; 40(5): 617-23.
31. Godot S, Gottenberg JE, Paternotte S, Pane I, Combe B, Sibilia J, et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken). 2013; 65(11): 1874-9.
32. Nishida K, Nasu Y, Hashizume K, Nakahara R, Ozawa M, Harada R, et al. Abatacept management during the perioperative period in patients with rheumatoid arthritis: report on eight orthopaedic procedures. Mod Rheumatol. 2014; 24(3): 544-5.
33. Saag K G, Teng G G, Patkar N M, Anuntiyo J, Finney C, Curtis J R, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008; 59(6): 762-84.
34. Ding T, Ledingham J, Luqmani R, Westlake S, Hyrich K, Lunt M, et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology (Oxford). 2010; 49(11): 2217-9.
35. Bongartz T, Halligan CS, Osmon DR, Reinalda MS, Bamlet WR, Crowson CS, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008; 59(12): 1713-20.
36. Scherrer CB, Mannion AF, Kyburz D, Vogt M, Kramers-de Quervain IA. Infection risk after orthopedic surgery in patients with inflammatory rheumatic diseases treated with immunosuppressive drugs. Arthritis Care Res (Hoboken). 2013; 65(12): 2032-40.